



## INFORMATION FOR PHYSICIANS

# FREQUENTLY ASKED QUESTIONS

**Cancer is a diagnosis that nobody wants to receive. It is an overwhelming time for patients, their families and clinicians. That's where Human Longevity, Inc. (HLI) steps in to be your health intelligence partner. Our HLIQ Oncology program is designed to analyze solid-state cancer tumors enabling individualized therapy selection and cancer management.**

Among a suite of products to utilize advancements in genomics and computing advances to inform and improve health outcomes, we offer HLIQ Oncology Analysis. Some variants in particular genes are strongly associated with health risk or disease, and that's where our HLIQ Oncology Analysis can help you better understand your patient's cancer and possible treatments. Below are Frequently Asked Questions to help guide your understanding.

### **Q: WHAT IS THE HLIQ ONCOLOGY ANALYSIS?**

**A:** HLIQ Oncology analyzes a patient's exome sequence to identify variants or mutations that can be targets for oncology treatments personalized specifically to a patient's cancer tumor cells.

HLIQ Oncology Analysis provides exome sequencing of a patient's germline DNA, tumor DNA, deep sequencing of cancer genes



## INFORMATION FOR PHYSICIANS

and RNA sequencing to help guide decisions toward cancer management. HLIQ Oncology Analysis provides additional information on the mutational burden of the tumor to further guide treatment options, including if a patient may be a candidate for immunotherapy.

### HLIQ ONCOLOGY CAN:

- Confirm diagnosis
- Identify related mutations specific to the tumor that may explain the cancer
- Identify if a patient may benefit from immunotherapy
- Determine inherited cancer risk
- Identify opportunities for off-label use of an approved drug
- Identify opportunities for clinical trial participation

### Q: HOW IS HLIQ ONCOLOGY ANALYSIS DIFFERENT?

**A:** HLI applies pioneering techniques utilizing the latest in genomics and technology to customize cancer insights. HLIQ Oncology provides you with an in-depth analysis of your patient's cancer to explore how it can guide your decisions towards personalized cancer therapy selection based on the specific genetic mutations of your patient's cancer employing state-of-the-art genomic profiling.

Other tests that do genetic testing on cancers typically provide a more limited scope of testing than the HLIQ Oncology. HLIQ Oncology analyzes the full exome of the patient and their tumor as opposed to a few cancer genes or limited panels of genes. Additionally, this test compares the exome sequence of a patient's normal DNA to that of their tumor to identify actionable targets that are specific to their tumor.

### Q: HOW CAN I REQUEST AN HLIQ ONCOLOGY ANALYSIS?

**A:** HLI works directly with oncologists, academic medical centers, and cancer treatment centers. If you are interested

in using this test for your patient, please call 844.838.3322, option 2, or contact [clientservices@humanlongevity.com](mailto:clientservices@humanlongevity.com).

### Q: WHAT KIND OF SPECIMENS ARE REQUIRED FOR HLIQ ONCOLOGY ANALYSIS?

**A:** HLI will need to obtain two specimens from your patient to process the HLIQ Oncology Analysis. These include a blood sample and the tissue sample from the patient's tumor. HLI will perform whole exome sequencing of both specimens to identify the genetic variants that are specific to the tumor and may be targets for cancer treatment.

The blood specimen is a standard blood draw and is used to sequence the patient's germline (normal) DNA.

For the tissue sample, HLI prefers to receive a Formalin-Fixed Paraffin Embedded Block (FFPE), but we will also accept FFPE slides.

- Tissue specimens should be fixed in 10% neutral buffer formalin solution (volume 10:1 of formalin to tissue).
  - Tissue block
  - If the tissue is only **available on slides, the test requires:**
    - 11 slides unstained total
    - 10 x 7-10  $\mu$ m
    - 1 x 4-5  $\mu$ m
    - Consecutive or adjacent sections
- **Are there any specimen types that will be rejected?**
  - Bone specimens if decalcified
  - Any tissue fixed in using anything other than 10% neutral buffer formalin solution (volume 10:1 of formalin to tissue).

If the patient has multiple tissue specimens, it is desirable to have the most recent samples and ones that provide the highest quality tumor tissue for analysis.



HLI is not able to process the HLIQ Oncology Analysis with only a tissue specimen. For the full specimen requirements, please refer to the Specimen Collection Requirements document.

**Q: HOW WILL MY PATIENT'S HLIQ ONCOLOGY ANALYSIS RESULTS BE DELIVERED TO ME?**

**A:** The HLIQ Oncology Analysis report will be delivered via the web-based HLIQ Physician Portal.

---

**INFORMATION  
FOR PHYSICIANS**